68819-84-1

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-BROMOBENZYLCARBAMATE is used as an organic synthetic intermediate for the production of a variety of drugs. Its unique structural composition allows it to serve as a key component in the synthesis of pharmaceutical compounds, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, TERT-BUTYL 4-BROMOBENZYLCARBAMATE is used as a building block for the creation of more complex molecules. Its versatility in chemical reactions makes it a valuable asset in the synthesis of a wide range of organic compounds, including those with potential applications in various industries such as agriculture, materials science, and chemical research.

InChI:InChI=1S/C12H16BrNO2/c1-12(2,3)16-11(15)14-8-9-4-6-10(13)7-5-9/h4-7H,8H2,1-3H3,(H,14,15)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 3959-07-7 4-Bromobenzylamine 
• 1228692-99-6 C₂₃H₂₁BrF₁₇NO₃ 
• 4248-19-5 tert-butyl carbazate 
• 1122-91-4 4-bromo-benzaldehyde 
• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 153171-22-3 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione 
• 107047-10-9 p-bromobenzylazide 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 66389-77-3 methyl tert-butyl iminodicarboxylate potassium salt 

Downstream Products

• 935528-04-4 (4-trimethylsilylprop-1-ynylbenzyl)carbamic acid tert-butyl ester 
• 935528-07-7 (4-ethynylphenyl)methanamine monohydrochloride 
• 214961-71-4 2-amino-4'-tert-butoxycarbonylaminomethyl-5-chlorobenzophenone 
• 1443787-05-0 (±)-tert-butyl (4-(1-oxo-2,3-dihydro-1H-inden-2-yl)benzyl)carbamate 

Relevant academic research and scientific papers

Synthesis and structure activity relationship of the first class of LXR inverse agonists

Liver X Receptors (LXRs) are members of the nuclear receptor family, and they play significant role in lipid and cholesterol metabolism. Moreover, they are key regulators of several inflammatory pathways. Pharmacological modulation of LXRs holds great pot

PROCESS FOR THE PREPARATION OF PANOBINOSTAT

The present invention relates to a new process for the preparation of Panobinostat and intermediates thereof.

Small molecule compound based on EZH2 protein degradation, and application thereof

The invention discloses a series of small molecule compounds capable of selectively degrading EZH2 protein, and application thereof. The compounds can be prepared into proper pharmaceutical dosage forms for EZH2-mediated related tumor treatment.

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure–activity relationships and X-ray crystallographic studies

USP7 as a deubiquitinase plays important roles in regulating the stability of some oncoproteins including MDM2 and DNMT1, and thus represents a potential anticancer target. Through comparative analysis of USP7 co-crystal structures in complex with the rep

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti

A Facile Synthesis of Ligands for the von Hippel-Lindau E3 Ligase

The proteolysis-targeting chimeras (PROTACs) have become an integral part of different stages of drug discovery. This growing field, therefore, benefits from advancements in all segments of the design of these compounds. Herein, an efficient and optimized synthetic protocol to various von Hippel-Lindau (VHL) ligands is presented, which enables easy access to multigram quantities of these essential PROTAC building blocks. Moreover, the elaborated synthesis represents a straightforward approach to further explore the chemical space of VHL ligands.

Optimization of globomycin analogs as novel gram-negative antibiotics

Discovery of novel classes of Gram-negative antibiotics with activity against multi-drug resistant infections is a critical unmet need. As an essential member of the lipoprotein biosynthetic pathway, lipoprotein signal peptidase II (LspA) is an attractive target for antibacterial drug discovery, with the natural product inhibitor globomycin offering a modestly-active starting point. Informed by structure-based design, the globomycin depsipeptide was optimized to improve activity against E. coli. Backbone modifications, together with adjustment of physicochemical properties, afforded potent compounds with good in vivo pharmacokinetic profiles. Optimized compounds such as 51 (E. coli MIC 3.1 μM) and 61 (E. coli MIC 0.78 μM) demonstrate broad spectrum activity against gram-negative pathogens and may provide opportunities for future antibiotic discovery.